The verdict
Our read at a glance.
Whether the approved emergency use of glucagon and the investigational use of glucagon-receptor agonism in obesity drugs support the broad metabolism and fat-loss claims made for glucagon analogs.
- The signal
- Glucagon is established and approved for treating severe low blood sugar. Adding glucagon-receptor activity to GLP-1-based drugs is supported by trials of dual and triple agonists such as survodutide and retatrutide, where it may add energy expenditure and liver-fat effects. Glucagon agonism on its own is not an approved weight treatment.
- The unknown
- How much the glucagon component contributes to the benefits and risks of the dual and triple agonists, and whether any standalone glucagon-agonist claim has a real basis.
- Our read
- An approved emergency hormone and a deliberate part of new obesity drugs, not a standalone fat-loss agent. Glucagon's rescue use is established and its receptor is a real target in dual and triple agonists, but glucagon agonism by itself is not an approved or proven weight treatment.
The mechanism
How it works.
Glucagon is the body's main counter-regulatory hormone to insulin: it binds the glucagon receptor on liver cells and tells them to break down stored glycogen and release glucose, which raises blood sugar and is why an injection rescues someone from severe hypoglycemia. The same receptor signaling also increases energy expenditure and can shift how the liver handles fat. Drug designers exploit that by building a measured amount of glucagon-receptor activity into GLP-1-based dual and triple agonists, so the appetite suppression of GLP-1 is paired with higher calorie burn.
Safety & regulatory boundary
The consequential part.
Approved glucagon products are for emergency treatment of severe low blood sugar, not for weight or metabolism. Glucagon-receptor agonism in obesity drugs is investigational and only studied as part of specific combination molecules. Raising glucagon activity can affect blood sugar and the heart, and emergency-glucagon approval does not validate metabolic or fat-loss claims. Research-labeled glucagon analogs are not approved products.
What's next
What we're watching.
Late-stage results for glucagon-containing dual and triple agonists, and any data on the specific contribution of glucagon agonism.
Context
Why this is discussed.
Glucagon is both a long-approved emergency hormone and a deliberate ingredient in the new dual and triple agonist obesity drugs, which makes its receptor a focus of metabolic interest.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE2 · RECRUITING · 2026-06
ClinicalTrials.gov · PHASE2 · NOT_YET_RECRUITING · 2027-01-01
ClinicalTrials.gov · PHASE2 · NOT_YET_RECRUITING · 2026-06-15
ClinicalTrials.gov · PHASE2/PHASE3 · RECRUITING · 2026-05-19
ClinicalTrials.gov · PHASE1 · RECRUITING · 2026-05-20
ClinicalTrials.gov · PHASE3 · RECRUITING · 2026-03-23
ClinicalTrials.gov · PHASE3 · RECRUITING · 2026-03-16
ClinicalTrials.gov · PHASE1 · ACTIVE_NOT_RECRUITING · 2026-03-05
Indexed literature (PubMed)12
le Roux CW et al. · Lancet Diabetes Endocrinol · 2024
Jastreboff AM et al. · N Engl J Med · 2023
Coskun T et al. · Cell Metab · 2022
Harrison SA et al. · J Hepatol · 2025
Ji L et al. · N Engl J Med · 2025
Holst JJ · Physiol Rev · 2007
Sanyal AJ et al. · N Engl J Med · 2024
Müller TD et al. · Mol Metab · 2019
Blüher M et al. · Diabetologia · 2024
Zimmermann T et al. · Mol Metab · 2022
Zafer M et al. · Aliment Pharmacol Ther · 2025
Katsi V et al. · Biomolecules · 2025
Keep reading